PIK3CA and neoplasm: Nevertheless, every preclinical model has inherent “tumor heterogeneity” issue since not all of the cells are 100% tumor cells or from the same clone of tumor (i.e. KRAS G12D tumor cell vs coexistent PIK3CA E542K tumor cell in the same tumor).